SCHEMBL19821270

SCHEMBL19821270

CC(C)OP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.56
AKT1 P31749 2/20 0.56
ESR1 P03372 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
CDC25A P30304 1/20 0.56
AGTR1 P30556 1/20 0.56
ADRA1A P35348 1/20 0.56
KCNH2 Q12809 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
PRKD3 O94806 1/20 0.47
PRKCG P05129 1/20 0.47
PRKCB P05771 1/20 0.47
PRKCA P17252 1/20 0.47
PRKCH P24723 1/20 0.47
PRKCI P41743 1/20 0.47
PRKCE Q02156 1/20 0.47
PRKCQ Q04759 1/20 0.47
PRKCZ Q05513 1/20 0.47
PRKCD Q05655 1/20 0.47
PRKD1 Q15139 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8561854 0.81 LMNA (0.61) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL19821623 0.81 SMN1; SMN2 (0.66) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL31643341 0.80 SMN1; SMN2 (0.49) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL19078863 0.80 SMN1; SMN2 (0.40) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL29395054 0.79 SMN1; SMN2 (0.64) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL28965396 0.79 SMN1; SMN2 (0.73) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL19689041 0.79 LMNA (0.59) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL12795706 0.78 SMN1; SMN2 (0.42) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL4972574 0.78 LMNA (0.86) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL20457127 0.78 SMN1; SMN2 (0.49) LMNAAKT1ESR1ADORA3CDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238427-A1 METHODS OF TREATING AN EYE DISORDER KODIAK SCIENCES INC. 2024-07-18 US disclosed
US-20240209160-A1 POLYMERIC DISPERSANTS FROM PHENYL GLYCIDYL ETHER STEPAN COMPANY 2024-06-27 US disclosed
US-11912784-B2 Methods of treating an eye disorder KODIAK SCIENCES INC. (US) 2024-02-27 US disclosed
US-20230250133-A1 METHODS OF PURIFYING A PRODUCT KODIAK SCIENCES GMBH (CH) 2023-08-10 US disclosed
US-20180147298-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS MODERNATX, INC. (US) 2018-05-31 US disclosed
US-20180028664-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS MODERNATX, INC. (US) 2018-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912784-B2 Methods of treating an eye disorder VEGFA, FLT4, FLT1 LMNA 3641/4885AKT1 4244/4885ESR1 4733/4885
US-20230250133-A1 METHODS OF PURIFYING A PRODUCT RCC2, SARS1, PHAX LMNA 1489/4885AKT1 3860/4885ESR1 4784/4885
US-20240238427-A1 METHODS OF TREATING AN EYE DISORDER ALDH1A2, PDE6D, CRYAB LMNA 2194/4885AKT1 4443/4885ESR1 4317/4885
US-20240209160-A1 POLYMERIC DISPERSANTS FROM PHENYL GLYCIDYL ETHER TYR, PAOX, NAPEPLD LMNA 4466/4885AKT1 1624/4885ESR1 2543/4885
US-20180147298-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS HDLBP, APOB, TSG101 LMNA 248/4885AKT1 3235/4885ESR1 4083/4885
US-20180028664-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS HDLBP, APOB, TSG101 LMNA 248/4885AKT1 3235/4885ESR1 4083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.